Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study

• Published in: Hepatology international Vol. 11; no. 2; pp. 188 - 198
• Main Authors: Sulkowski, Mark S., Fessel, Walford J., Lazzarin, Adriano, Berenguer, Juan, Zakharova, Natalia, Cheinquer, Hugo, Côté, Pierre, Dieterich, Douglas, Gadano, Adrian, Matthews, Gail, Molina, Jean-Michel, Moreno, Christophe, Pineda, Juan Antonio, Pulido, Federico, Rivero, Antonio, Rockstroh, Jurgen, Hernandez, Dennis, McPhee, Fiona, Eley, Timothy, Liu, Zhaohui, Mendez, Patricia, Hughes, Eric, Noviello, Stephanie, Ackerman, Peter
• Format: Journal Article
• Language: English
• Published: New Delhi Springer India 01.03.2017; Springer Nature B.V
• Subjects: Adult; Aged; Antiviral Agents - administration & dosage; Antiviral Agents - adverse effects; Antiviral Agents - therapeutic use; Coinfection - drug therapy; Coinfection - virology; Colorectal Surgery; Drug Therapy, Combination; Female; Hepacivirus - drug effects; Hepacivirus - genetics; Hepatitis C virus; Hepatitis C, Chronic - complications; Hepatitis C, Chronic - drug therapy; Hepatology; HIV Infections - complications; HIV Infections - drug therapy; Humans; Imidazoles - administration & dosage; Imidazoles - adverse effects; Imidazoles - therapeutic use; Interferon-alpha - administration & dosage; Interferon-alpha - adverse effects; Interferon-alpha - therapeutic use; Lentivirus; Male; Medicine; Medicine & Public Health; Middle Aged; Original Article; Polyethylene Glycols - administration & dosage; Polyethylene Glycols - adverse effects; Polyethylene Glycols - therapeutic use; Recombinant Proteins - administration & dosage; Recombinant Proteins - adverse effects; Recombinant Proteins - therapeutic use; Retroviridae; Ribavirin - administration & dosage; Ribavirin - therapeutic use; Surgery; Treatment Outcome; Young Adult; Daclatasvir; HIV/HCV coinfection; Peginterferon alfa-2a/ribavirin; HCV GT-1

Background Daclatasvir (DCV) is a potent, pangenotypic, hepatitis C virus (HCV) non-structural protein 5A inhibitor with low potential for drug interactions with antiretroviral therapy (ART). We evaluated the safety and efficacy of DCV plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in HIV-1/HCV g...